Zyomyx to Develop Biochips Using Dyax s Phage Display Technology

Mar 27, 2001

NEW YORK, March 27 - In an effort to develop its protein biochips, Zyomyx said Tuesday it has licensed phage display antibody technology from Dyax.

The agreement is the second antibody collaboration for Zyomyx, which first teamed up with Cambridge Antibody Technology (CAT) last December for access to antibodies in CAT's phage display libraries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Science

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

Science in Coach

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Funny Side of Science

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

When the FDA Plays Hardball

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."

Main menu